Poland· PL-100399097
Norepinephrine Sopharma
A norepinephrine product containing noradrenalinum, registered in Poland by Sopharma Warszawa Sp. z o.o.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Norepinephrine is registered in 13 of 19 countries.
Countries holding a registration under ATC C01CA03 (norepinephrine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Norepinephrine · ATC C01CA03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Noradrenalinum
- Manufacturer
- Sopharma Warszawa Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- C01CA03
- ATC class
- Norepinephrine
- Defined daily dose
- 6 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 6
- gtin03800010647496
- gtin03800010647472
- gtin03800010647489
- gtin03800010647410
- gtin03800010653954
- gtin03800010653947
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
89 interactions on record for norepinephrine.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Norepinephrine · interactions on record
89 records
- 3 severe
- 86 moderate
Most severe, free to view
- CocaineN01BC01severe
- DoxepinN06AA12severe
- CocaineR02AD03severe
- PhentermineA08AA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C01CA03
Norepinephrine, as other registers publish it.
- PolandLevonorZakłady Farmaceutyczne POLPHARMA S.A.
- United StatesLEVOPHEDHospira, Inc.
- United StatesLEVOPHEDHospira, Inc.
- BelgiumLevophed 8 mg/4 mlHospira Benelux
- United StatesLEVOPHED(R) NOREPINEPHRINE BITARTRATEHF Acquisition Co LLC, DBA HealthFirst
- BelgiumMivuxin 5 µg/mlLaboratoire Aguettant
- BelgiumMivuxin 5 µg/mlLaboratoire Aguettant
- DenmarkMykronorLaboratoire Aguettant
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/058685dd-3339-409e-9a4c-922fe1cc38d7 GET /v1/drugs/058685dd-3339-409e-9a4c-922fe1cc38d7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "1 mg/ml",
"packaging": "03800010647496 ¦ Lz ¦ 134186\n5 amp. 1 ml\n03800010647472 ¦ Lz ¦ 134187\n5 amp. 4 ml\n03800010647489 ¦ Lz ¦ 134188\n10 amp. 1 ml\n03800010647410 ¦ Lz ¦ 134189\n10 amp. 4 ml\n03800010653954 ¦ Lz ¦ 164007\n5 amp. 10 ml\n03800010653947 ¦ Lz ¦ 164008\n10 amp. 10 ml",
"substance": "Noradrenaliny winian 2 mg",
"common_name": "Noradrenalinum",
"pl_product_id": "100399097",
"pozwolenie_nr": "25572",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about norepinephrine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.